10-Q: Nexalin Technology Reports Second Quarter 2024 Results, Highlights Regulatory Progress and Financial Position

Nexalin Technology's Q2 2024 report details financial results, ongoing regulatory efforts, and strategic developments in the neurostimulation device market.

Summary

• Nexalin Technology reported a net loss of $1.28 million for the three months ended June 30, 2024, and a net loss of $2.33 million for the six months ended June 30, 2024.
• The company's revenue for the three months ended June 30, 2024, was $26,840, and $105,511 for the six months ended June 30, 2024.
• Operating expenses totaled $1.32 million for the three months and $2.46 million for the six months ended June 30, 2024.
• The company has a joint venture in China for the development and distribution of its Gen-2 devices, with Nexalin owning 48% of the venture.
• Nexalin received regulatory approval for its Gen-2 device in Brazil and has commenced sales in Oman.
• The company completed a public offering on July 1, 2024, raising approximately $5.25 million in gross proceeds.
• As of August 6, 2024, Nexalin had approximately $5.2 million in cash and short-term investments on hand.
• The company is working towards FDA clearance for its Gen-3 device and is planning clinical trials in the US and China.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments such as increased revenue, regulatory approvals, and a successful capital raise, the company is still operating at a loss, has a significant accumulated deficit, and faces regulatory and operational risks. The sentiment is neutral to slightly negative due to the financial challenges and the need for further development and regulatory approvals.

Positives

• Revenue increased by 60% for the six months ended June 30, 2024, compared to the same period in 2023.
• Gross profit margin improved to 84.5% for the six months ended June 30, 2024.
• The company successfully raised $5.25 million through a public offering on July 1, 2024.
• Regulatory approvals were obtained in Brazil and Oman for the Gen-2 device.
• The company has a joint venture in China that is progressing with clinical development, marketing, and sales of Gen-2 devices.

Negatives

• The company reported a net loss of $2.33 million for the six months ended June 30, 2024.
• Operating expenses increased by 44% for the six months ended June 30, 2024.
• The company has a significant accumulated deficit of $79.4 million as of June 30, 2024.
• The company's operating activities consume the majority of its cash resources.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company has a significant accumulated deficit and has incurred substantial losses.
• The company's ability to continue as a going concern is dependent on its ability to generate revenue and raise additional capital.
• The company is subject to regulatory risks associated with obtaining FDA clearance for its devices.
• The company faces risks related to its joint venture in China, including economic, political, and legal uncertainties.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company is subject to the risk of not maintaining its Nasdaq listing.

Future Outlook

The company plans to continue the development of its Gen-3 device, conduct clinical trials, and seek regulatory approvals in the US and other territories. They also intend to expand their commercialization efforts and explore strategic business development initiatives. The company expects to incur operating losses for at least the next two years.

Management Comments

• The Nexalin research team believes that the new 15 milliamp Gen-2 and Gen-3 devices can penetrate deeper into the brain and stimulate associated structures of mental illness.
• The Nexalin regulatory team has made a strategic decision to develop strategies for pilot trials and/or pivotal trials in various mental health disease states.
• Management has evaluated the significance of the conditions as of June 30, 2024 and have concluded that we have sufficient cash and short-term investments in the amount of approximately $5.2 million on hand on August 6, 2024 to satisfy our anticipated cash requirements for the next twelve months from the issuance of these financial statements.

Industry Context

The company operates in the neurostimulation device market, which is experiencing growth due to the increasing prevalence of mental health disorders. Nexalin is positioning itself to compete with traditional treatments by offering a non-invasive, drug-free alternative. The company's focus on advanced waveform technology and a virtual clinic model aligns with current trends in telehealth and personalized medicine.

Comparison to Industry Standards

• Nexalin's revenue of $105,511 for the first six months of 2024 is relatively low compared to established medical device companies, but it is a significant increase compared to the same period in 2023.
• The company's gross profit margin of 84.5% is strong, indicating efficient cost management in production.
• The company's operating expenses are high relative to its revenue, which is typical for early-stage companies in the medical device industry that are investing heavily in research and development.
• The company's net loss of $2.33 million for the first six months of 2024 is significant, but it is not uncommon for companies in this stage of development.
• Compared to companies like NeuroMetrix and Neuronetics, which also focus on neurostimulation, Nexalin is still in an earlier stage of commercialization and has a smaller revenue base.
• The company's joint venture in China is a strategic move to access a large market, similar to how other medical device companies have expanded internationally.
• The company's focus on a virtual clinic model is a unique approach that could differentiate it from competitors.

Management Changes

Legal Proceedings

• The company is involved in a lawsuit filed by Sarah Veltz, alleging unpaid wages and sexual harassment. The trial is set for November 18, 2024.
• The company is engaged in settlement discussions with the Employment Development Department (EDD) of the State of California regarding the classification of certain workers.

Related Party Transactions

• The company has a joint venture with Wider Come Limited, a related party, for the development and distribution of its Gen-2 devices in China.
• The company has a consulting agreement with U.S. Asian Consulting Group, LLC, whose members are shareholders in the company.
• The company leases office space through IIcom Strategic Inc., controlled by the Chief Executive Officer.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance, regulatory progress, and capital raising activities.
• Employees are impacted by the company's financial stability and strategic direction.
• Customers are impacted by the availability and effectiveness of the company's products.
• Suppliers are impacted by the company's ability to pay for goods and services.
• Creditors are impacted by the company's ability to repay its debts.

Next Steps

• The company plans to continue the development of its Gen-3 device.
• The company will conduct clinical trials for the Gen-3 device in the US and China.
• The company will seek regulatory approvals for its devices in the US and other territories.
• The company will expand its commercialization efforts.
• The company will explore strategic business development initiatives.

Key Dates

Keywords

neurostimulation, mental health, FDA, clinical trials, joint venture, China, regulatory approval, medical device, anxiety, insomnia, depression, public offering, financial results